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BACKGROUND
Current strategies for preventing severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2) infection are limited to nonpharmacologic interventions. Hydroxy-
chloroquine has been proposed as a postexposure therapy to prevent coronavirus 
disease 2019 (Covid-19), but definitive evidence is lacking.
METHODS
We conducted an open-label, cluster-randomized trial involving asymptomatic 
contacts of patients with polymerase-chain-reaction (PCR)–confirmed Covid-19 in 
Catalonia, Spain. We randomly assigned clusters of contacts to the hydroxychloro-
quine group (which received the drug at a dose of 800 mg once, followed by 400 mg 
daily for 6 days) or to the usual-care group (which received no specific therapy). 
The primary outcome was PCR-confirmed, symptomatic Covid-19 within 14 days. 
The secondary outcome was SARS-CoV-2 infection, defined by symptoms compatible 
with Covid-19 or a positive PCR test regardless of symptoms. Adverse events were 
assessed for up to 28 days.
RESULTS
The analysis included 2314 healthy contacts of 672 index case patients with Covid-19 
who were identified between March 17 and April 28, 2020. A total of 1116 contacts 
were randomly assigned to receive hydroxychloroquine and 1198 to receive usual 
care. Results were similar in the hydroxychloroquine and usual-care groups with 
respect to the incidence of PCR-confirmed, symptomatic Covid-19 (5.7% and 6.2%, 
respectively; risk ratio, 0.86 [95% confidence interval, 0.52 to 1.42]). In addition, 
hydroxychloroquine was not associated with a lower incidence of SARS-CoV-2 
transmission than usual care (18.7% and 17.8%, respectively). The incidence of adverse 
events was higher in the hydroxychloroquine group than in the usual-care group 
(56.1% vs. 5.9%), but no treatment-related serious adverse events were reported.
CONCLUSIONS
Postexposure therapy with hydroxychloroquine did not prevent SARS-CoV-2 in-
fection or symptomatic Covid-19 in healthy persons exposed to a PCR-positive 
case patient. (Funded by the crowdfunding campaign YoMeCorono and others; 
BCN-PEP-CoV2 ClinicalTrials.gov number, NCT04304053.)
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Coronavirus disease 2019 (Covid-19) is a rapidly emerging infectious disease caused by the severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2). Among 
contacts of persons with Covid-19, the percent-
age in whom new cases develop (secondary attack 
rate) has been estimated at 10 to 15%.1-4 The 
current infection-control strategy is based on 
nonpharmacologic interventions, including hand 
hygiene, use of face masks, social distancing, 
and isolation of case patients and contacts.5 The 
effectiveness of isolation depends on the prompt-
ness of the intervention, the level of contact 
tracing, and the level of isolation adherence.6 
Unfortunately, real-world constraints for imple-
menting full effective measures have resulted in 
the spread of SARS-CoV-2 in many countries.
Postexposure prophylaxis of healthy contacts 
is among the measures used for outbreak control 
of several infectious diseases (e.g., pandemic 
influenza).7 No agent is known to be effective in 
preventing SARS-CoV-2 infection or Covid-19, 
but two aminoquinolines — hydroxychloroquine 
and chloroquine — are among the drugs that 
have shown antiviral activity in the laboratory.8 
In vitro results showed that these drugs blocked 
SARS-CoV-2 viral spread in cell cultures9-11 and 
that hydroxychloroquine was more effective at 
impairing SARS-CoV-2 viral replication than 
chloroquine.11 The results of one randomized, 
controlled trial of hydroxychloroquine for post-
exposure prophylaxis of Covid-19 have been re-
ported.12 However, concerns have been raised 
about the trial design. Of the participants with 
confirmed or probable Covid-19 (primary out-
come), fewer than 20% had a positive polymerase-
chain-reaction (PCR) test for SARS-COV-2; the 
rest received a diagnosis on the basis of symp-
toms alone.
In the Barcelona Postexposure Prophylaxis 
Study against SARS-CoV-2 (BCN-PEP-CoV2), we 
investigated the efficacy and safety of hydroxy-
chloroquine to prevent secondary PCR-confirmed, 
symptomatic Covid-19 and SARS-CoV-2 infection 
in contacts exposed to a PCR-positive case patient 
with Covid-19 during the early stages of the out-
break in Catalonia, the region with the second 
highest number of Covid-19 cases in Spain. (Even 
when not specified, symptomatic Covid-19 here-




We included asymptomatic adults (≥18 years of 
age) who had a recent history of close-contact 
exposure to a PCR-confirmed case patient with 
Covid-19 (i.e., >15 minutes within 2 m, up to 7 days 
before enrollment), who had no Covid-19–like 
symptoms during the 2 weeks before enroll-
ment, and who had an increased risk of infection 
(e.g., a health care worker, a household contact, 
a nursing-home worker, or a nursing-home resi-
dent). Trial candidates were tested by PCR assay 
for SARS-CoV-2 infection at baseline. We included 
candidates with either a negative or positive PCR 
test at baseline to assess the prophylactic and pre-
emptive effect of hydroxychloroquine treatment, 
respectively. All eligibility criteria are listed in 
the Supplementary Appendix and the trial proto-
col, both available with the full text of this ar-
ticle at NEJM.org.
Trial Design and Oversight
This was an open-label, phase 3, cluster-random-
ized trial conducted from March 17 to April 28, 
2020, during the early stages of the Covid-19 
outbreak, in three of nine health administrative 
regions in Catalonia, Spain (total target popula-
tion, 4,206,440) (Fig. S1 in the Supplementary 
Appendix). Trial candidates were screened with 
the use of the electronic registry of the national 
health information system.13
The trial was supported by the crowdfunding 
campaign YoMeCorono (https://www . yomecorono 
. com/ ), Generalitat de Catalunya, Zurich Seguros, 
Synlab Diagnósticos, Laboratorios Rubió, and 
Laboratorios Gebro Pharma. Laboratorios Rubió 
donated and supplied the hydroxychloroquine 
(Dolquine). The sponsors had no role in the 
conduct of the trial, the analysis, or the decision 
to submit the manuscript for publication. The 
trial protocol and subsequent amendments were 
approved by the institutional review board at Hos-
pital Germans Trias i Pujol and the Spanish 
Agency of Medicines and Medical Devices. All the 
participants provided written informed consent.
Trial Procedures
We defined trial clusters (called rings) of healthy 
persons (contacts) who were epidemiologically 
linked to a PCR-positive case patient with Covid-19 
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(index case patient). All the contacts in a ring 
simultaneously underwent cluster randomization 
(in a 1:1 ratio) to either the hydroxychloroquine 
group or the usual-care group. Contacts in the 
former group received hydroxychloroquine 
(Dolquine) at a dose of 800 mg on day 1, followed 
by 400 mg once daily for 6 days; the dosing regi-
men was based on pharmacokinetic simulations. 
Contacts in the usual-care group received no 
specific therapy. After cluster randomization, we 
verified the selection criteria of individual candi-
dates, obtained informed consent, and revealed 
the trial-group assignments. In accordance with 
national guidelines, all the contacts were quar-
antined.
All the contacts were visited at home or in the 
workplace on day 1 (enrollment) and day 14 (final 
outcome measurement) for assessment of health 
status and collection of nasopharyngeal swabs. 
Symptoms were monitored by telephone on days 
3 and 7. Contacts in whom symptoms developed 
at any time point were visited at home within 
24 hours for assessment of health status and col-
lection of nasopharyngeal swabs. Safety (i.e., fre-
quency and severity of adverse events), medication 
adherence (i.e., treatment and number of doses 
taken), and crossover (i.e., unplanned conversion 
from usual care to hydroxychloroquine) were as-
sessed with the use of contact reports collected 
in telephone interviews on days 3, 7, and 28.
All testing of nasopharyngeal swabs for 
SARS-CoV-2 and analyses to determine viral load 
were performed by technicians who were un-
aware of previous PCR results, trial-group assign-
ments, and response. PCR amplification was 
based on the 2019 Novel Coronavirus Real-Time 
RT [reverse transcriptase]–PCR Diagnostic Panel 
guidelines of the Centers for Disease Control 
and Prevention.14 For quantification, a standard 
curve was built with the use of 1:5 serial dilu-
tions of a SARS-CoV-2 plasmid (with known con-
centration) and run in parallel with 300 study 
samples. The accuracy of the qualitative estimate 
(i.e., cycle threshold [Ct] values) was determined 
by correlation with the quantitative measure on 
300 samples (Fig. S2). The coefficient of correla-
tion between the two methods was 0.93, which 
permitted the use of qualitative Ct data to esti-
mate viral load in contacts. Detection of IgM and 
IgG antibodies was performed by means of fin-
gertip blood testing on the day 14 visit with the 
use of a rapid test (VivaDiag COVID-19).15
Outcomes
The primary outcome was the onset of a PCR-
confirmed, symptomatic Covid-19 episode, defined 
as symptomatic illness (at least one of the fol-
lowing symptoms: fever, cough, difficulty breath-
ing, myalgia, headache, sore throat, new olfactory 
or taste disorder, or diarrhea) and a positive 
RT-PCR test for SARS-CoV-2. The primary out-
come was assessed in all asymptomatic contacts, 
irrespective of the baseline PCR result; in a post 
hoc analysis, we explored the outcome sepa-
rately in contacts with a positive baseline PCR 
test and those with a negative baseline PCR test. 
The time until the primary event was defined as 
the number of days until the onset of symptom-
atic illness from the date of exposure and from 
the date of randomization.
The secondary outcome was the incidence of 
SARS-CoV-2 infection, defined as either the 
RT-PCR detection of SARS-CoV-2 in a nasopharyn-
geal specimen or the presence of any of the afore-
mentioned symptoms compatible with Covid-19. 
The rationale for this outcome was to encom-
pass definitions of Covid-19 used elsewhere.12,16 
Contacts who were hospitalized or who died and 
whose hospital and vital records listed Covid-19 
as the main diagnosis (including PCR confirma-
tion) were also considered for the primary and 
secondary outcomes.
Statistical Analysis
With an enrollment target of 95 clusters per trial 
group17 ― 15 contacts per cluster and intraclass 
correlation of 1.0 ― the initial design provided 
a power of 90% to detect a between-group dif-
ference of 10 percentage points in the incidence 
of PCR-confirmed, symptomatic Covid-19, with 
an expected incidence of 5% in the hydroxychlo-
roquine group and 15% in the usual-care group. 
Owing to the limited information available by 
March 2020 regarding the cluster size and the 
incidence of Covid-19 after exposure, the protocol 
prespecified a sample-size reestimation at the in-
terim analysis. Reestimation was aimed at main-
taining the ability (at 80% power) to detect a be-
tween-group difference of 3.5 percentage points 
in the incidence of primary-outcome events 
(3.0% in the hydroxychloroquine group and 
6.5% in the usual-care group), yielding 320 clus-
ters per trial group with 3.5 contacts per cluster, 
an intraclass correlation of 1.0, and no provision 
for crossover.
The New England Journal of Medicine 
Downloaded from nejm.org on October 15, 2021. For personal use only. No other uses without permission. 
 Copyright © 2021 Massachusetts Medical Society. All rights reserved. 
n engl j med 384;5 nejm.org February 4, 2021420
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
The primary efficacy analysis was performed 
in the intention-to-treat population. Multiple im-
putation by chained equations was applied to ac-
count for missing data.18,19 The assumption that 
unobserved values were missing at random was 
deemed to be appropriate because we could not 
find any pattern among the missing values.20 A 
complete-case analysis and a per-protocol analy-
sis were conducted as sensitivity analyses. The 
cumulative incidence of trial outcomes was com-
pared at the individual level with the use of a 
binomial regression model with robust sandwich 
standard errors to account for grouping within 
clusters.21 We defined a generalized linear mod-
el with a binomial distribution and a log-link 
function to estimate the risk ratio as a measure 
of effect.22 The analyses were adjusted for the 
baseline variables of age, sex, geographic region, 
and time of exposure. We performed additional 
prespecified analyses to assess the consistency 
of treatment effects in subgroups defined ac-
cording to the viral load of the contact at base-
line, viral load of the index case patient, place of 
exposure, and time of exposure to the index case 
patient. The reported confidence intervals have 
not been adjusted for multiple comparisons and 
cannot be used to infer effects. Survival curves 
according to trial group for time-to-event out-
comes were compared with the use of a Cox 
proportional-hazards model with a cluster-level 
frailty term to adjust for clustering.23 The sig-
nificance threshold was set at a two-sided alpha 
value of 0.05, unless otherwise indicated. All 
statistical analyses were conducted with R soft-
ware, version 3.6.2.24
R esult s
Characteristics of the Trial Participants
Between March 17 and April 28, 2020, we as-
sessed 754 index case patients with Covid-19 for 
eligibility; 672 of them were selected for defin-
ing the corresponding clusters, which included 
4399 contacts (Fig. 1). A total of 1874 contacts 
(42.6%) were not enrolled because they met ex-
clusion criteria, including having Covid-19–like 
symptoms before enrollment (537 contacts). In 
addition, 40 of 2525 enrolled contacts (1.6%) 
were excluded from the intention-to-treat analy-
sis because of screening failure, which resulted 
in an intention-to-treat population of 2485, of 
whom 171 (6.9%) had missing data imputed on 
outcome analysis. During follow-up, 64 contacts 
had a protocol deviation regarding the interven-
tion (per-protocol population of 2250 contacts).
The demographic, clinical, and epidemiologic 
characteristics of the contacts at baseline were 
similar in the two trial groups (Table 1). The 
mean (±SD) age of the contacts was 48.6±19.0 
years, and the PCR test at baseline was negative 
in 87.8% (2000 of 2279). Overall, 39.4% of the 
contacts (912 of 2314) reported at least one 
chronic health condition. The median interval 
from exposure to enrollment was 4.0 days (inter-
quartile range, 3.0 to 6.0). The size of the clus-
ters was similar in the two groups (median, 2.0 
contacts in the hydroxychloroquine group and 
2.0 in the usual-care group). Exposure was pre-
dominantly from an index case patient with a 
moderate-to-high viral load (107 to 1012 copies 
per milliliter), which was reported in 307 of 549 
index case patients (55.9%) for whom viral-load 
data were available. Health care workers and 
nursing home workers accounted for 1395 of 2314 
contacts (60.3%); 626 (27.1%) were household 
contacts, and 293 (12.7%) were nursing home 
residents. Overall, 1555 contacts (67.2%) report-
ed routine use of masks at the time of exposure, 
and 144 contacts (6.2%) continued to sleep in the 
same room as the index case patient.
Primary Outcome
During the 14-day follow-up, 138 of 2314 con-
tacts (6.0%) had a PCR-confirmed, symptomatic 
Covid-19 episode. The results were similar in the 
hydroxychloroquine group (64 of 1116; 5.7%) 
and the usual-care group (74 of 1198; 6.2%) (risk 
ratio, 0.86; 95% confidence interval [CI], 0.52 to 
1.42) (Table 2), with the use of multiple-imputa-
tion techniques to account for 171 missing values. 
The complete-case analysis (Table S1) and per-
protocol analysis (Table S2) showed results that 
were similar to those in the primary analysis. 
The incidence of each of the components of the 
primary outcome did not differ substantially 
between the groups (Table 2).
Overall, the incidence of symptomatic Covid-19 
was higher among contacts who had a positive 
PCR test at baseline than among those who had 
a negative test (20.4% [64 of 314 contacts] vs. 
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Figure 1. Screening and Randomization.
The safety population (2497 contacts; 1197 in the hydroxychloroquine group and 1300 in the usual-care group) in-
cluded all those in the intention-to-treat population (except 28 in the hydroxychloroquine group who did not receive 
the trial medication) plus 40 (19 in the hydroxychloroquine group and 21 in the usual-care group) who were classi-
fied as having a screening failure. The intention-to-treat population (2485 contacts; 1206 in the hydroxychloroquine 
group and 1279 in the usual-care group) included 2314 who had data available for analysis of the primary outcome 
plus 171 (90 in the hydroxychloroquine group and 81 in the usual-care group) with no available polymerase-chain- 
reaction (PCR) assay results at day 14 who had missing responses imputed.
4399 Contacts in 672 clusters
were defined
754 Index case patients were assessed
for eligibility
82 Were not considered for inclusion
(i.e., clusters not defined) because of delayed 
reporting >7 days after start of symptoms
1874 Contacts were not considered for inclusion
32 Had known history of cardiac arrhythmia
or other coexisting condition
33 Had dementia or severe mental illness
12 Received contraindicated medication
537 Had Covid-19–like symptoms at baseline
1193 Did not sign informed-consent form
4 Had exposure >7 days earlier
4 Were <18 yr of age
15 Were pregnant or were breast-feeding
3 Had severe Covid-19
2 Were receiving hydroxychloroquine
39 Had other reason
1300 in 334 clusters were assigned to
usual-care group
1225 in 338 clusters were assigned
to hydroxychloroquine group
21 Had screening failure
10 Were symptomatic at baseline
11 Did not sign informed-consent
form
19 Had screening failure
10 Were symptomatic at baseline
2 Were <18 yr of age
7 Did not sign informed-consent
form
1279 Were included in intention-to-treat
population
1198 Had data available for evaluation
of primary outcome
81 Had missing responses imputed
1206 Were included in intention-to-treat
population
1116 Had data available for evaluation
of primary outcome
90 Had missing responses imputed
12 Were excluded owing to crossing
over to hydroxychloroquine
52 Were excluded
28 Did not receive any dose
of hydroxychloroquine
18 Had treatment adherence
<80%
6 Discontinued trial owing 
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Contacts of index patients
Age — yr 48.6±18.7 48.7±19.3
Female sex — no. (%) 813 (72.8) 875 (73.0)
Viral load on PCR at baseline — no./total no. (%)
Undetectable: <104 copies/ml 958/1102 (86.9) 1042/1177 (88.5)
104 to 106 copies/ml 78/1102 (7.1) 88/1177 (7.5)
107 to 109 copies/ml 58/1102 (5.3) 42/1177 (3.6)
1010 to 1012 copies/ml 8/1102 (0.7) 5/1177 (0.4)
Coexisting disease — no. (%)
None 660 (59.1) 742 (61.9)
Cardiovascular disease 82 (7.3) 104 (8.7)
Respiratory disease 47 (4.2) 35 (2.9)
Metabolic disease 68 (6.1) 66 (5.5)
Nervous system disease 97 (8.7) 97 (8.1)
No. of days of exposure before intervention — no. of contacts (%)
≤3 440 (39.4) 411 (34.3)
4–6 551 (49.4) 668 (55.8)
≥7 125 (11.2) 119 (9.9)
Type of contact with index case patient — no. (%)
Household contact 302 (27.1) 324 (27.0)
Health care worker 131 (11.7) 130 (10.9)
Nursing home worker 550 (49.3) 584 (48.7)
Nursing home resident 133 (11.9) 160 (13.4)
Routine use of mask — no. (%)†
Yes 730 (65.4) 825 (68.9)
No 251 (22.5) 256 (21.4)
Missing data 135 (12.1) 117 (9.8)
Sleeping in the same room as the index case patient — no. (%)
Yes 78 (7.0) 66 (5.5)
No 834 (74.7) 951 (79.4)
Missing data 204 (18.3) 181 (15.1)
Clusters
Median no. of days of exposure before enrollment (IQR) 4.0 (3.0–6.0) 4.0 (3.0–6.0)
Median no. of contacts per cluster (IQR) 2.0 (1.0–3.0) 2.0 (1.0–3.0)
Viral load of the index case patient — no./total no. (%)
Undetectable: <104 copies/ml‡ 42/259 (16.2) 47/290 (16.2)
104 to 106 copies/ml 68/259 (26.3) 85/290 (29.3)
107 or 108 copies/ml 81/259 (31.3) 83/290 (28.6)
109 to 1012 copies/ml 68/259 (26.3) 75/290 (25.9)
*  Plus–minus values are means ±SD. Percentages may not total 100 because of rounding. IQR denotes interquartile 
range, and PCR polymerase chain reaction.
†  Routine use of mask refers to use at the time of exposure.
‡  The prescreening PCR test was positive at the designated hospital laboratory before enrollment, but the test was nega-
tive (undetectable, <104 copies per milliliter) at the research laboratory from the swab collected on day 1.
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3.7% [74 of 2000]) (Table 2). Hydroxychloro-
quine was ineffective in preventing symptomatic 
Covid-19 both in contacts with a positive PCR 
test at baseline and in those with a negative test.
We observed an overall increased risk of 
symptomatic Covid-19 with increasing viral load 
of the contact at baseline (Fig. S3A) and increas-
ing viral load of the index case patient (Fig. S3B). 
The viral load of contacts who went on to have 
symptomatic Covid-19 increased 4 log10 copies per 
milliliter throughout the follow-up, whereas that 
of contacts without Covid-19 remained unchanged 
(Fig. S3C). Prespecified subgroup analysis of the 
primary outcome did not reveal substantial be-
tween-group differences in the risk of symptom-
atic Covid-19 according to the viral load of the 
contact at baseline, the viral load of the index 
case patient, the duration of exposure, or the 
type of contact (Fig. 2). The survival analysis of 
the time to a primary-outcome event showed 
similar patterns in the two groups regarding 
symptomatic Covid-19 onset from enrollment 
(median, 4.0 days in the hydroxychloroquine 
group and 5.0 days in the usual-care group; 








no. of events/no. of contacts (%)
Primary outcome: PCR-confirmed, symptomatic Covid-19
All patients‡ 64/1116 (5.7) 74/1198 (6.2) 0.86 (0.52–1.42)
Clinical and laboratory criteria 49/1116 (4.4) 60/1198 (5.0)
Hospital or vital-records criteria 15/1116 (1.3) 14/1198 (1.2)
PCR-negative at baseline 29/958 (3.0) 45/1042 (4.3) 0.68 (0.34–1.34)
Clinical and laboratory criteria 24/958 (2.5) 37/1042 (3.6)
Hospital or vital-records criteria 5/958 (0.5) 8/1042 (0.8)
PCR-positive at baseline 35/158 (22.2) 29/156 (18.6) 1.02 (0.64–1.63)
Clinical and laboratory criteria 25/158 (15.8) 23/156 (14.7)
Hospital or vital-records criteria 10/158 (6.3) 6/156 (3.8)
Secondary outcomes§
Covid-19, either symptomatically compatible or PCR 
positivity regardless of symptoms
179/958 (18.7) 185/1042 (17.8) 1.03 (0.77–1.38)
Laboratory criteria¶ 58/958 (6.1) 67/1042 (6.4)
Clinical criteria‖ 144/958 (15.0) 150/1042 (14.4)
Hospital or vital-records criteria 5/958 (0.5) 8/1042 (0.8)
Serologic positivity on day 14 137/958 (14.3) 91/1042 (8.7) 1.57 (0.94–2.62)
IgM positivity 100/958 (10.4) 70/1042 (6.7)
IgG positivity 118/958 (12.3) 82/1042 (7.9)
*  Percentages are for contacts for whom complete data were available. Covid-19 denotes coronavirus disease 2019.
†  Risk ratios were adjusted for contact-level variables (age, sex, geographic region, and time of exposure), and multiple 
imputation by chained equations17 was applied to handle missing data. The assumption that unobserved values were 
missing at random was deemed to be appropriate because we could not find any pattern among the missing values. 
Because primary and secondary outcomes were dichotomous variables, the imputation models were based on a two-
level logistic-regression model to account for clustering.18 Five estimates from each imputed data set were combined 
according to Rubin rules.16
‡  Marginal estimates of effects for the primary outcome were 5.6% in the hydroxychloroquine group and 6.3% in the 
usual-care group (risk difference, −0.6 percentage points)
§  Contacts who were PCR-positive at baseline were excluded from the secondary outcomes. The components of the sec-
ondary outcomes are not mutually exclusive.
¶  These contacts with PCR-confirmed Covid-19 were either symptomatic or asymptomatic.
‖  These contacts had symptoms compatible with Covid-19, regardless of the results of PCR testing.
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hazard ratio, 0.9 [95% CI, 0.6 to 1.5]) and from 
exposure (median, 8.0 days and 8.0 days in the 
respective groups; hazard ratio, 1.0 [95% CI, 
0.6 to 1.6]) (Fig. S4).
Secondary Outcomes
Of the 2000 contacts who tested negative for 
SARS-CoV-2 on the baseline PCR test, 364 (18.2%) 
either became PCR-positive or had symptoms 
compatible with Covid-19 during the follow-up 
period (Table 2), without a substantial difference 
between the trial groups (18.7% [179 of 958] 
with hydroxychloroquine and 17.8% [185 of 1042] 
with usual care; risk ratio, 1.03 [95% CI, 0.77 to 
1.38]). Positivity for virus-specific IgG or IgM 
antibodies was higher in the hydroxychloroquine 
group than in the usual-care group (14.3% [137 
of 958] vs. 8.7% [91 of 1042]). Of 125 contacts 
who became PCR-positive during follow-up, 30 
(24.0%) were seropositive on day 14 (Fig. S5).
Adherence and Safety
Full adherence to the trial intervention was 95.1% 
(1138 of 1197) in the hydroxychloroquine group 
and 97.5% (1268 of 1300) in the usual-care group. 
In the safety population, 671 of 1197 contacts 
(56.1%) in the hydroxychloroquine group and 77 
of 1300 (5.9%) in the usual-care group had at 
least one adverse event during 14 days of follow-
up (Table 3). The most frequent treatment-related 
adverse events among contacts given hydroxy-
chloroquine were gastrointestinal (diarrhea, nau-
sea, and abdominal pain) and nervous system 
disorders (drowsiness and headache) (Table S6). 
A total of 31 serious adverse events were reported, 
14 in the hydroxychloroquine group and 17 in 
the usual-care group; none of these events were 
thought to be related to hydroxychloroquine or 
usual care by the independent pharmacovigilance 
consultants (Table S7). Six adverse events of spe-
cial interest were observed, including five episodes 
of self-limited heart palpitations potentially re-
lated to hydroxychloroquine (Table S8). Further 
safety data are provided in the Supplementary 
Appendix.
Discussion
In our trial, postexposure prophylaxis with hy-
droxychloroquine did not prevent SARS-CoV-2 
infection or symptomatic Covid-19 in asymptom-
atic contacts exposed to a PCR-positive index case 
Figure 2. Subgroup Analyses of the Primary Outcome, According to Epidemiologic Risk Factors (Intention-to-Treat 
Population).
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patient. The overall attack rate for PCR-confirmed, 
symptomatic Covid-19 was 6.0%, excluding con-
tacts who were not enrolled because they had 
symptoms before the baseline assessment. Con-
tacts who received hydroxychloroquine and those 
who received usual care had a similar incidence 
of symptomatic Covid-19 (5.7% and 6.2%, re-
spectively). Our trial tested two possible effects 
of postexposure therapy: prophylaxis in contacts 
with a negative PCR test at baseline and preemp-
tive therapy in contacts with a positive PCR test 
at baseline (i.e., to prevent progression of asymp-
tomatic infection to disease). This dual scenario 
mirrors a real-life setting, in which the PCR re-
sult of contacts exposed to a known Covid-19 
index case is usually not immediately available. 
Hydroxychloroquine showed no efficacy as pro-
phylactic therapy for contacts who were PCR-
negative at baseline. Similarly, among the con-
tacts who were PCR-positive at baseline (13.6%), 
hydroxychloroquine had no apparent efficacy as 
early preemptive therapy. A baseline positive PCR 
test increased the risk of symptomatic Covid-19 
in our cohort, but a high percentage of the con-
tacts with this laboratory result (79.6%) did not 
go on to have symptomatic disease, thus reinforc-
ing the need to quarantine or to increase testing 
of contacts even if they are asymptomatic. In ad-
dition, of importance to public health decision 
making is that the higher the SARS-CoV-2 viral 
load in an index case patient was, the greater was 
the risk of transmission to contacts.
Hydroxychloroquine also did not reduce the 
transmission of SARS-CoV-2 (18.7%, as compared 
with 17.8% with usual care) or the incidence of 
seropositivity. It is notable that the overlap of a 







(N = 1300) P Value
Reported full adherence to trial intervention — no. (%) 1138 (95.1) 1268 (97.5)
Adverse events — no. (%)
Any adverse event 671 (56.1) 77 (5.9) <0.001
Cardiac disorder: palpitations 5 (0.4) 1 (0.1)
Gastrointestinal disorder: diarrhea, abdominal pain, vomiting 510 (42.6) 33 (2.5)
Nervous system disorder: headache, taste change, dizziness 260 (21.7) 32 (2.5)
General disorder: myalgia, fatigue, malaise 103 (8.6) 10 (0.8)
Intensity of adverse event — no. (%) <0.001†
Grade 1: mild 573 (47.9) 44 (3.4)
Grade 2: moderate 68 (5.7) 14 (1.1)
Grade 3: severe 13 (1.1) 2 (0.2)
Grade 4: potentially life-threatening 11 (0.9) 10 (0.8)
Grade 5: death 5 (0.4) 8 (0.6)




Adverse event of special interest: cardiac — no. of events§ 5 1
*  The safety population included all the contacts who received either hydroxychloroquine or usual care.
†  The overall P value for grading is shown.
‡  None of the serious adverse events were adjudicated as being related to hydroxychloroquine or usual care by the inde-
pendent pharmacovigilance consultants. Death and hospitalization were not mutually exclusive; five deaths occurred at 
the hospital, whereas other contacts died at a nursing home.
§  Cardiac disorders were all episodes of palpitations; three of five events in the hydroxychloroquine group were adjudicat-
ed as being possibly related to the trial drug by the independent pharmacovigilance consultants. Details are provided in 
the Supplementary Appendix.
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positive PCR test and a positive serologic test was 
low, which could be related to the reported low 
sensitivity of the rapid test for IgM and IgG anti-
bodies within 10 days after symptom onset,15 the 
low incidence of seroconversion among asymp-
tomatic contacts,25 or the higher risk of a false 
negative PCR result during the initial stage of 
infection.16 With respect to safety, we observed a 
higher incidence of adverse events in the hydroxy-
chloroquine group than in the usual-care group, 
albeit with low severity. In this open-label trial, 
the psychological components in the treated 
group cannot be ruled out. Furthermore, the side 
effects were mainly gastrointestinal, whereas 
only 5 of 1479 events (0.3%) in the hydroxychlo-
roquine group were considered to be heart-relat-
ed; therefore, our data do not corroborate previ-
ously published data on the increased risk of 
cardiac arrhythmia.26 The safety results need to 
be interpreted on the basis of the dose used, 
length of treatment, and lack of electrocardio-
graphic monitoring in the trial.
The strengths of this trial are the use of a 
PCR test and viral-load quantification at base-
line, at day 14, and potentially when the contact 
was ill, and the measurement of viral load of the 
index case patient to estimate the risk of trans-
mission. In addition, we included very elderly 
persons (e.g., >90 years of age) in nursing homes. 
The trial has some limitations. Unlike the com-
mon procedure in clinical trials, the signing of 
the informed-consent form took place after clus-
ter randomization. Nevertheless, trial-group as-
signments were revealed to contacts after con-
sent was obtained; therefore, we believe that the 
strategy for concealing trial-group assignments 
was appropriate to prevent contacts from choos-
ing to participate or not to participate. Because 
of the urgency of the pandemic, we did not in-
clude a placebo group in the trial, which may 
have affected the reporting of adverse events. 
However, the laboratory staff who performed PCR 
tests remained unaware of the trial-group as-
signments.
Despite the promising in vitro results that 
placed hydroxychloroquine among the leading 
candidates for Covid-19 treatment and prophy-
laxis,27-29 there are no compelling data to suggest 
that hydroxychloroquine is effective. We provide 
evidence on the lack of efficacy of postexposure 
prophylaxis therapy with hydroxychloroquine to 
prevent SARS-CoV-2 infection or symptomatic 
Covid-19.
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